Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 7/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15968637 | 0.94 | LPL (0.38) | LPLLIPGCSF1RBACE1CA1 | |
| SCHEMBL25803846 | 0.89 | SYK (0.44) | LPLLIPGCSF1RPDE4ABACE1 | |
| SCHEMBL129705 | 0.85 | PDE4A (0.49) | PDE4A | |
| SCHEMBL23484600 | 0.85 | CSNK2A1 (0.36) | LPLLIPGCSF1RBACE1CA1 | |
| SCHEMBL25932163 | 0.84 | PDE4D (0.38) | CSF1RPDE4A | |
| SCHEMBL18003997 | 0.83 | POLB (0.38) | LPLLIPGCSF1RPDE4ABACE1 | |
| SCHEMBL22816386 | 0.82 | CSNK2A1 (0.39) | LPLLIPGCSF1RPDE4ABACE1 | |
| SCHEMBL24930071 | 0.82 | PDE4A (0.37) | LPLLIPGPDE4ABACE1CA1 | |
| SCHEMBL129694 | 0.82 | PDE4A (0.52) | PDE4A | |
| SCHEMBL30717778 | 0.82 | RORC (0.44) | LPLLIPGCSF1RBACE1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086767-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086767-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR77 | LPL 3073/4885LIPG 3181/4885CSF1R 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.